Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus
Primary Purpose
Diabetes Mellitus, Non-Insulin-Dependent
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
stem cells
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Non-Insulin-Dependent
Eligibility Criteria
Inclusion Criteria:
• Patients with type 2 diabetes mellitus between 30 and 65 years of age.
- Duration of diabetes ≥ 5 years.
- Failure to triple OHA in optimal doses {glimepiride (4 gm), metformin(2-2.5 gm) and pioglitazone(15mg)}.
- Requiring insulin therapy for last six month
- On stable doses of insulin (≥0.4 IU/kg/day, Vildagliptin, metformin (2 gm), pioglitazone (15mg) for last three months.
- GAD antibody negative status.
Exclusion Criteria:
- Patients with type 1 diabetes mellitus or secondary diabetes
- Patients with serum creatinine > 1.5 mg/dL
- Abnormal liver function tests (defined as value of transaminases > 3 times the upper value of normal or serum bilirubin higher than normal for the reference value for the laboratory).
- History of cholecystitis/ cholelithiasis/ cholecystectomy.
- Seropositivity for HIV, HBsAg and HCV.
- History of myocardial infarction or unstable angina or any cardiovascular events in the previous 3 months.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Intravenous
superior pancreaticoduodenal
splenic artery
Arm Description
stem cells will be injected through intravenously in the subjects
stem cells
stem cells will be injected through splenic in the subjects
Outcomes
Primary Outcome Measures
Increase in glucagon stimulated C peptide level
Secondary Outcome Measures
Full Information
NCT ID
NCT02585505
First Posted
October 19, 2015
Last Updated
October 22, 2015
Sponsor
Postgraduate Institute of Medical Education and Research
1. Study Identification
Unique Protocol Identification Number
NCT02585505
Brief Title
Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus
Official Title
Tissue Distribution of F18-FDG Labeled Autologous Bone Marrow Derived Stem Cells in Patients With Type2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Postgraduate Institute of Medical Education and Research
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Stem cells have promising potential in treating diabetes. However the therapeutic outcome in diabetic patients will profoundly depend on their delivery to pancreas. Our objective is to label stem cells with PET tracer F18-FDG to carry out in vivo cell tracking. The labeled stem cells will be given through different routes (intravenous and intraarterial)and tissue distribution studied. Patients will be followed up for the next 6 months. Glucagon stimulated C peptide will be measured at baseline and at 6 months and HOMA IR and HOMA beta will be calculated.
Detailed Description
Our objective is to label stem cells with PET tracer F18-FDG to carry out in vivo cell tracking. The labeled stem cells will be given through different routes (intravenous and intraarterial)and tissue distribution studied. Patients will be followed up for the next 6 months. Glucagon stimulated C peptide will be measured at baseline and at 6 months and HOMA IR and HOMA beta will be calculated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Non-Insulin-Dependent
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intravenous
Arm Type
Active Comparator
Arm Description
stem cells will be injected through intravenously in the subjects
Arm Title
superior pancreaticoduodenal
Arm Type
Active Comparator
Arm Description
stem cells
Arm Title
splenic artery
Arm Type
Active Comparator
Arm Description
stem cells will be injected through splenic in the subjects
Intervention Type
Procedure
Intervention Name(s)
stem cells
Intervention Description
stem cell will be injected
Primary Outcome Measure Information:
Title
Increase in glucagon stimulated C peptide level
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
• Patients with type 2 diabetes mellitus between 30 and 65 years of age.
Duration of diabetes ≥ 5 years.
Failure to triple OHA in optimal doses {glimepiride (4 gm), metformin(2-2.5 gm) and pioglitazone(15mg)}.
Requiring insulin therapy for last six month
On stable doses of insulin (≥0.4 IU/kg/day, Vildagliptin, metformin (2 gm), pioglitazone (15mg) for last three months.
GAD antibody negative status.
Exclusion Criteria:
Patients with type 1 diabetes mellitus or secondary diabetes
Patients with serum creatinine > 1.5 mg/dL
Abnormal liver function tests (defined as value of transaminases > 3 times the upper value of normal or serum bilirubin higher than normal for the reference value for the laboratory).
History of cholecystitis/ cholelithiasis/ cholecystectomy.
Seropositivity for HIV, HBsAg and HCV.
History of myocardial infarction or unstable angina or any cardiovascular events in the previous 3 months.
12. IPD Sharing Statement
Learn more about this trial
Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus
We'll reach out to this number within 24 hrs